Product Description
an optimised oromucosal formulation of a currently marketed drug for the new use of treatment of xerostomia (dry mouth) in advanced cancer patients
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eagle
Company Location: Eastern America
Company CEO: Scott Tarriff
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Xerostomia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2011-000978-53 |
Phase II PoC study of APD515 v1.1 | P2 |
Completed |
Xerostomia |
2012-12-20 |
2022-03-13 |
Treatments |
|
NCT01331746 |
DX10008 | P2 |
Completed |
Xerostomia |
2012-12-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|